AU2011340160B2 - Composition for inhibiting the growth of mammalian hair - Google Patents
Composition for inhibiting the growth of mammalian hair Download PDFInfo
- Publication number
- AU2011340160B2 AU2011340160B2 AU2011340160A AU2011340160A AU2011340160B2 AU 2011340160 B2 AU2011340160 B2 AU 2011340160B2 AU 2011340160 A AU2011340160 A AU 2011340160A AU 2011340160 A AU2011340160 A AU 2011340160A AU 2011340160 B2 AU2011340160 B2 AU 2011340160B2
- Authority
- AU
- Australia
- Prior art keywords
- hair growth
- inhibiting
- hair
- active agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 30
- 210000004209 hair Anatomy 0.000 title claims abstract description 16
- 230000012010 growth Effects 0.000 title claims abstract description 5
- 230000003779 hair growth Effects 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000002502 liposome Substances 0.000 claims description 20
- 235000004443 Ricinus communis Nutrition 0.000 claims description 17
- 240000000528 Ricinus communis Species 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 10
- 239000006286 aqueous extract Substances 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 6
- 239000002537 cosmetic Substances 0.000 claims 4
- 150000003904 phospholipids Chemical class 0.000 claims 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 3
- -1 DOPE Chemical compound 0.000 claims 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 3
- 229940106189 ceramide Drugs 0.000 claims 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000003780 hair follicle Anatomy 0.000 abstract description 8
- 210000004919 hair shaft Anatomy 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 3
- 239000000419 plant extract Substances 0.000 abstract description 3
- 239000000284 extract Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 239000010409 thin film Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 238000004018 waxing Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 238000005868 electrolysis reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Birds (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to inhibiting hair growth. Particularly, the invention relates to composition for and method of inhibiting growth of mammalian hair with plant extract using liposomal delivery system which damages the hair follicle, thereby disabling it to form a normal hair shaft.
Description
Compositionsfor inhibiting mammalian hair growth FIELD OF INVENTION:
The invention relatesto inhibiting hair growth.
Particularly, the invention relates to composition for and method of inhibiting growth of mammalian hair with plant extract using liposomal delivery system which damagesthe hair follicle , thereby disabling it to form a normal hair shaft. INTRODUCTION:
Generally normal body hair growth is tolerated. But if there is excessive unwanted hair growth it affectsthe self-esteem of the person because of the social stigma.
Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and therapeutic anti-androgens. These conventional procedures generally have drawbacks associated with them. PRIOR ART:
Asa rule normal body hair growth is tolerated. But if there isexcessive unwanted hair growth it affectsthe self-esteem of the person.
Various procedures have been employed to remove unwanted hair, including shaving, depilatory creams or lotion, waxing, plucking, electrolysis, therapeutic anti-androgens and laser. These conventional procedures generally have drawbacks associated with them.
The inventor herself has filed following patents on the subject, incorporated here as reference.
Indian patent application no IN/ 837/ 2004 dated 13th August 2004 (Granted Patent no: 237834) USpatent publication no US2006-0034952 A1 dated 16th February 2006 USpatent publication no US2008-0145330 A1 dated 19th June 2008 PCT patent application no PCT/ IN2005/000190 10th June 2005 SDuth Africa Granted patent no: 2007/2024 United Kingdom Granted Patent no: GB2434533 Australia Patent Application no: 2005270843 (Granted)
Indian Patent Application No337/MUIW2006 dated 09th March 2006 Indian Patent Application No998/MUIW2006 dated 16th March 2006 Indian Patent Application No 1296/ MUIW2006 dated 2131 August 2006
The inventor has discussed the use of the actives in different formsderived from the castor beansand related group of actives (cytotoxic lectins) for the inhibition of hair and hair f oli i cl e related actionsin these patent applications.
Castor bean is well known for its lipid constituent, castor oil and its medicinal properties especially as a purgative.
The ancient Science of Ayurveda describes many medicines made of castor oil and beans for variousapplicationssuch asfor general pain, inflammation, headache, abdominal pain, fever, asthma, cough, leucoderma, piles, Vaatnashak, used externally as a paste to treat inflammatory skin conditions, boils, carbuncles, abscesses, inflammation of the middle ear, and migraines.
Though the topical applications of castor are well known, they are not meant for the above-mentioned application.
Most of all, the above prior art other than patent applications filed by Inventor, does not mention use of the composition for specifically inhibit mammalian hair growth. Whereas, the claimed composition for specifically inhibiting mammalian hair growth is a novel invention and would offer an inexpensive method for inhibiting mammalian hair growth.
This invention seeksto overcome the limitationsof the prior art.
The object of this invention is to provide for a composition for inhibiting mammalian hair growth.
Another object of this invention is to provide for a composition for inhibiting mammalian hair growth from castor beans.
Another object of this invention is to provide for a composition for inhibiting mammalian hair growth from follicular delivery of aqueous extract of castor beans.
Another object of this invention isto provide for a composition using vesicular carriers which deliver the active i.e. Rcin in the extract directly to the hair follicle without causing allergic reaction.
Another object of this invention is to provide for a cytotoxic lectin (e.g. Rcin) composition using vesicular carriers for hair growth inhibition wherein purification of cytotoxic lectin (e.g. Rcin) i s not necessary.
Another object of this invention is to provide for a composition for inhibiting mammalian hair growth from follicular delivery of liposomized castor beansextract.
Another object of this invention isto provide for a composition that could be applied topically to the skin so asto damage the follicle, resulting in follicular destruction, thereby disabling it to form a hair shaft.
Another object of this invention is to provide the composition in the form of a paste, cream or gel which iseasy to apply, hasaesthetic appeal and hasgood spread ability.
Another object of this invention isto provide for a composition in the form of a paste, cream or gel that leavesno stainson application and isfree of preservatives.
Another object of this invention is to provide for a composition which could be packed conveniently i n jarsor tubes.
BACKGFOJND OF THE INVENTION
The invention relatesto inhibiting hair growth.
Particularly, the invention relates to composition for and method of inhibiting growth of mammalian hair with plant extract using liposomal delivery system which damagesthe hair follicle, thereby disabling it to form a normal hair shaft.
SUMMARY OF THE INVENTION
The present invention comprises of compositions for topical application for inhibiting unwanted mammalian hair growth by applying an effective amount of the composition to the skin of individuals in need to inhibit hair, including facial areas, legs, arms, armpits, and torso; irrespective of gender of the subject. The composition comprises of a hair-growth-inhibiting active agent dispersed in a dermatologically acceptable vehicle such as but not limiting to oil in water emulsion, gels, sustained release polymer films, sprays, soaps etc. 9milarly, vesicular carrierslike liposomes can be used for the selective follicular delivery of the hair-growth-inhibiting agent.
TECHNICAL FIELD
Rcin, which represents the type II ribosome inactivating proteins, isthe active ingredient in the castor bean that inactivatesthe hair follicle disabling it to form the hair shaft. Apart from ricin & its isomers, there is a group of allergens that are present in the castor bean. Rcin is water-soluble in nature, but also is present in castor oil in low concentrations. So, both aqueous extract and oil fraction can be used together or separately for the hair-growth inhibition. However, the allergic fraction causesboth immediate and delayed hypersensitivity reactions. So, it calls for the treatment of the extract to remove the allergens. Various extraction and purification procedures of the herbal extract arewell knowntothose skilled in the art. However, the present invention describes an innovative solution wherein castor bean extract, without purifying Rcin, can be used by encapsulating in a carrier like liposome, neosome or microspheres. Use of such vesicular carriers results in delivery of the active i.e. Rcin in the extract directly to the hair follicle without causing allergic reaction.
Before administration of the composition, herein described, in a preferred embodiment the hair is removed from the follicle e.g. by waxing or plucking or alternatively by other methods like shaving, depilation. Methods of hair removal which remove the hair from the follicle are known to initiate anagen, the growth phase of the hair cycle and also it exposes the hair follicle assembly responsible for the synthesis of hair shaft to the action of the composition herein described.
The topical compositions are the formulationscontaining therapeutically effective amountsof the respective active agent and pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such asbut not limitingto pH adjusting and buffering agents, toxicity adjusting agentsand the like, vesicular carriers like liposomes, microspheres, neosomes for carrying the active agent to the hair follicle, along with the usual components of the particular carrier like e.g. for oil in water emulsion, stearic acid and its derivatives, cetyl alcohol and its derivatives, mineral oils, citric acid, preservatives, fragrance, colours etc. or other such topical compositions as described in different pharmaceutical publications, resulting in aesthetically pleasing and easy to use formulations.
Examples:
Crude aqueousextractsof castor beansare used for liposome formulations.
Compositions:
Number of gel and oil in water emulsions were prepared using varying concentrations of the liposome suspension for animal aswell as human experiments.
Oil in water emulsion:
Mineral oil 26%
Cetyl alcohol 0.52%
Searicacid 0.94%
Cetostearyl alcohol 0.94%
Scdium alginate 0.36 %
Triethanolamine 0.1 %
Methyl Paraben 0.2%
Propyl paraben 0.01 %
Purified Water q.s.
Liposome suspension 10- 50 %
Gel:
Carbopol 940 1 %
Triethanolamine 1 %
Purified Water q.s.
Liposome suspension 10- 50 %
Liposome encapsulation Example1:
Liposomes were prepared using Phospholipon 90 G (Lipoid) 10 mg and cholesterol 1.5 mg by ethanol injection method.
Example 2:
Liposomes were prepared using Phospholipon 90 G (Lipoid) 10 mg and cholesterol 1.5 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by centrifugation.
Example 3:
Liposomes were prepared using Phospholipon 90 G (Lipoid) 15 mg by thin film formation method and hydrated with the extract (15 ml). Un-encapsulated extract is removed by centrifugation.
Example 4
Liposomes were prepared using Phospholipon 90 G (Lipoid) 10 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by centrifugation.
Example 5
Liposomes were prepared using &ya lecithin (Himedia) 10 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by centrifugation.
Example 6
Liposomes were prepared using Sbya lecithin (Himedia) 9 mg and DOPE 1 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract isremoved by centrifugation.
Example 7
Liposomes were prepared using Soya lecithin (Himedia) 8 mg and DOPE 2 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract isremoved by centrifugation.
Ali the formulations mentioned above showed reduction i n the number of hai r follicles, reduction in the darkness, length and thickness of the hair. Overall they changed the appearance of re-growing hair, both in animal experiments (mice) and humans. Also, the subjectsdid not show any adverse reaction to their skin.
At the end of the description of the invention, it should be understood that without departing from the spirit of the invention or the essential characteristics, it might be embodied in other variations. The embodiments described here should be considered as illustrative but not as restrictive.
Ali variations and forms, which come within the meaning and the range of equivalency of the claim, are intended to be embraced therein.
Claims (9)
1. A topical composition for inhibiting the growth of mammalian hair comprising a. Hair growth inhibiting active agent which is a liposome-encapsulated crude aqueous extract of Ricinus communis, wherein hair growth inhibiting active agent is prepared using phospholipids selected from lecithin, phosphatidylcholine (PC), phosphatidylethanolamine(PE), phosphatidylserine(PS), DOPE, ceramide and crude aqueous extract of Ricinus communis. b. Dermatologically acceptable vehicle c. Water (q.s.), wherein the hair growth inhibiting active agent is dispersed in a dermatologically acceptable vehicle so as to provide 10- 50% hair growth inhibiting active agent to the skin.
2. A topical composition for inhibiting mammalian hair growth as claimed in claim 1 wherein the composition is in the form of oil in water emulsion or gel.
3. A topical composition according to claim 1, wherein the liposomes are prepared using phospholipids
4. A topical composition according to claim 3, wherein the phospholipids used are selected from lecithin, phosphatidylcholine (PC), phosphatidylethanolamine(PE), phosphatidylserine(PS), DOPE, ceramide.
5. A topical composition according to claim 1, wherein the liposomes optionally contain cholesterol or cholesteryl esters.
6. A cosmetic method of inhibiting mammalian hair growth, comprising providing and applying a topical composition of any of the preceding claim to mammalian skin.
7. A cosmetic method of inhibiting mammalian hair growth as claimed in claim 6, wherein the topical composition is applied after removal of hair.
8. A cosmetic method of inhibiting human hair growth comprising a. Providing a safe method to manufacture a hair growth inhibiting active agent which is liposome-encapsuiated crude aqueous extract of Ricinus communis b. Dispersing the hair growth inhibiting active agent in a dermatologically acceptable vehicle c. Application of the cosmetic composition comprising 1050 % hair growth inhibiting active agent, which is liposome-encapsulated crude aqueous extract of Ricinus communis, to the skin.
9. Use of liposome encapsulated crude aqueous extract of Ricinus communis in the manufacture of a topical composition for inhibiting the mammalian hair growth; wherein the liposomes are manufactured using crude aqueous extract of Ricinus communis and phospholipids selected from lecithin, phosphatidylcholine (PC), phosphatidylethanolamine(PE), phosphatidylserine(PS), DOPE, ceramide and dispersed in the composition so as to provide 10 to 50 % liposome suspension.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1738/MUM/2010 | 2010-12-08 | ||
| IN1738MU2010 | 2010-12-08 | ||
| PCT/IB2011/055431 WO2012077024A1 (en) | 2010-12-08 | 2011-12-02 | Composition for inhibiting the growth of mammalian hair |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011340160A1 AU2011340160A1 (en) | 2013-07-18 |
| AU2011340160B2 true AU2011340160B2 (en) | 2017-10-12 |
Family
ID=46206659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011340160A Ceased AU2011340160B2 (en) | 2010-12-08 | 2011-12-02 | Composition for inhibiting the growth of mammalian hair |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2011340160B2 (en) |
| GB (1) | GB2499769B (en) |
| WO (1) | WO2012077024A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827510A (en) * | 1997-09-29 | 1998-10-27 | Mesquitta; Trevor E. | Hair growth preparation |
| WO2000000002A2 (en) * | 1998-06-09 | 2000-01-06 | Massachusetts Institute Of Technology | Method for current sharing in a superconducting current lead |
| US20060034952A1 (en) * | 2004-08-13 | 2006-02-16 | Kondhalkar Mrinmayee B | Agent for inhibiting the growth of mammalian hair |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| US20060257509A1 (en) * | 2003-10-10 | 2006-11-16 | Zimmerman Amy C | Cosmetic composition and methods |
| US20050084470A1 (en) * | 2003-10-15 | 2005-04-21 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin care and cleansing compositions containing oil seed product |
-
2011
- 2011-12-02 AU AU2011340160A patent/AU2011340160B2/en not_active Ceased
- 2011-12-02 GB GB1311617.3A patent/GB2499769B/en not_active Expired - Fee Related
- 2011-12-02 WO PCT/IB2011/055431 patent/WO2012077024A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827510A (en) * | 1997-09-29 | 1998-10-27 | Mesquitta; Trevor E. | Hair growth preparation |
| WO2000000002A2 (en) * | 1998-06-09 | 2000-01-06 | Massachusetts Institute Of Technology | Method for current sharing in a superconducting current lead |
| US20060034952A1 (en) * | 2004-08-13 | 2006-02-16 | Kondhalkar Mrinmayee B | Agent for inhibiting the growth of mammalian hair |
| US20080145330A1 (en) * | 2004-08-13 | 2008-06-19 | Mrinmayee Bhushan Kondhalkar | Agent for inhibiting the growth of mammalian hair |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2499769A8 (en) | 2013-09-04 |
| GB2499769B (en) | 2018-04-18 |
| AU2011340160A1 (en) | 2013-07-18 |
| WO2012077024A1 (en) | 2012-06-14 |
| GB201311617D0 (en) | 2013-08-14 |
| GB2499769A (en) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2605405T3 (en) | Compositions containing anti-acne agents and their use | |
| CN106580798B (en) | Full-effect eye cream and preparation method thereof | |
| DE69627988T3 (en) | INHIBITORS OF NO SYNTHASE | |
| RU2151589C1 (en) | Anti-inflammatory agent, composition containing this agent, method of treatment of patients with dermatological and systemic inflammatory diseases | |
| Narshana et al. | An overview of dandruff and novel formulations as a treatment strategy | |
| CN109152716B (en) | Taurine and aloe vera synergistic anti-irritant compositions and methods | |
| US9775789B2 (en) | Topical liposome compositions containing phenolic anti-inflammatory agents and their methods of preparation | |
| ES2209080T3 (en) | ROSACE EXTRACT AS AN BRADIQUININE ANTAGONIST. | |
| Sheth et al. | Pityriasis capitis: Causes, pathophysiology, current modalities, and future approach | |
| JP2003531860A (en) | Olive seed plant extract and its use as NO synthase inhibitors | |
| JP2003532644A (en) | Plant extracts of Vitis vinifera species as NO synthase inhibitors and their use | |
| JP2005047910A (en) | Sebum secretion-inhibiting composition | |
| WO2015147137A1 (en) | Ceramide-formulated external agent composition | |
| AU2011340160B2 (en) | Composition for inhibiting the growth of mammalian hair | |
| KR101626473B1 (en) | Composition for external application to the skin containing cyclohexane dicarboxylic acid derivatives | |
| JP2004307470A (en) | Use of monoesters or diesters of cinnamic acid or its derivatives with vitamin C as NO donor | |
| JP2004307469A (en) | Use of N-arylmethyleneethylenediaminetriacetate, N-arylmethyleneiminodiacetate or N, N'-diarylmethyleneethylenediamine acetate as NO donor | |
| KR20150050982A (en) | Cosmetic composition and external composition comprising acylated saponin for anti-inflammatory | |
| KR20150050981A (en) | Cosmetic composition and external composition comprising steroidal lactones for anti-inflammatory | |
| KR20150050980A (en) | Cosmetic composition and external composition comprising Withania somnifera for anti-inflammatory | |
| JP6782962B2 (en) | TRPM8 activator, cooling sensitizer, cosmetics and oral composition | |
| JPH1192353A (en) | External preparation for skin for inhibiting sebum synthesis | |
| Mukherjee et al. | Nonionic surfactant nanovesicles for cosmeceutical applications | |
| KR20150050983A (en) | Cosmetic composition and external composition comprising glucosyl withanolides for anti-inflammatory | |
| JP3193617B2 (en) | Refreshing agent and composition for human body |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted | ||
| NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 13 MAY 2016 TO 13 AUG 2017 IN WHICH TO GAIN ACCEPTANCE HAS BEEN FILED |
|
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO GAIN ACCEPTANCE HAS BEEN EXTENDED TO 13 AUG 2017 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |